PDX Model

MSK-LX95-R

Sex: Male

Histology: Small cell lung cancer

Key Mutations: TP53 G154Afs*16, RB1 X203_splice, PTEN L181Wfs*13,

MYCN Amplified

Molecular Characteristics: MSK-IMPACT, whole exome sequencing

Matched Normal: Yes

Treatment: cisplatin + etoposide, extensive cisplatin and etoposide

treatment in PDX

Site: Lung

Paired: Yes

Comments: Chemoresistant

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes.

MSK Office of Technology Development Contact: Alexandra Buga, MS, MBA, Licensing Associate, T: 646-888-1078, e-mail: bugaa@mskcc.org.

Stage of Development

Ready to use

Indications